Ophthalmic Drugs Market

Executive Summary

Ophthalmic Drugs Market was valued at US $36.37 billion in 2021 and is projected to grow at 8.56% CAGR over the forecast period to reach US $59.53 billion by 2027. Ophthalmic Drugs Market represented US $5.51 billion opportunity over 2019-2021 and estimated to create US $23.17 billion opportunity in 2027 over 2021.

Ophthalmic Drugs from Consainsights analyses the Ophthalmic Drugs Market in the Life Sciences industry over the forecast period to 2027.

Ophthalmic Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Ophthalmic Drugs segmentation includes Drug Class, Product Type and Geography.

Based on the Drug Class, the Ophthalmic Drugs analysis covers Anti-glaucoma Drug, Dry eye Drug, Ophthalmic Anti-allergy/Inflammatory, Retinal Drug, Anti-infective Drugs, Other Drugs.

In Drug Class segment, Anti-glaucoma Drug segment has highest cagr growth of 7.57%.

Based on the Product Type, the Ophthalmic Drugs analysis covers OTC Drug, Prescription Drug.

In Product Type segment, OTC Drug segment has highest cagr growth of 7.57%.

Based on the region, the Ophthalmic Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Aerie Pharmaceuticals Inc., Abbive (Allergan), Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Hoya Corporation, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Drug Class

Introduction

In 2021, Anti-glaucoma Drug segment has the highest revenue of US $14.64 billion and is expected to grow at CAGR of 7.57% by 2027 Anti-glaucoma Drug segment has highest cagr growth of 7.57%.

Anti-glaucoma Drug

Anti-glaucoma Drug segment was valued at US $12.42 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $23.97 billion by 2027. Anti-glaucoma Drug segment represented US $2.22 billion opportunity over 2019-2021 and estimated to create US $9.33 billion opportunity in 2027 over 2021.

Dry eye Drug

Dry eye Drug segment was valued at US $7.09 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $13.67 billion by 2027. Dry eye Drug segment represented US $1.27 billion opportunity over 2019-2021 and estimated to create US $5.32 billion opportunity in 2027 over 2021.

Ophthalmic Anti-allergy/Inflammatory

Ophthalmic Anti-allergy/Inflammatory segment was valued at US $4.24 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $8.18 billion by 2027. Ophthalmic Anti-allergy/Inflammatory segment represented US $0.76 billion opportunity over 2019-2021 and estimated to create US $3.18 billion opportunity in 2027 over 2021.

Retinal Drug

Retinal Drug segment was valued at US $2.94 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $5.67 billion by 2027. Retinal Drug segment represented US $0.52 billion opportunity over 2019-2021 and estimated to create US $2.21 billion opportunity in 2027 over 2021.

Anti-infective Drugs

Anti-infective Drugs segment was valued at US $2.67 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $5.15 billion by 2027. Anti-infective Drugs segment represented US $0.48 billion opportunity over 2019-2021 and estimated to create US $2.00 billion opportunity in 2027 over 2021.

Other Drugs

Other Drugs segment was valued at US $1.50 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $2.90 billion by 2027. Other Drugs segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $1.13 billion opportunity in 2027 over 2021.

Product Type

Introduction

In 2021, OTC Drug segment has the highest revenue of US $21.67 billion and is expected to grow at CAGR of 7.57% by 2027 OTC Drug segment has highest cagr growth of 7.57%.

OTC Drug

OTC Drug segment was valued at US $18.38 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $35.47 billion by 2027. OTC Drug segment represented US $3.28 billion opportunity over 2019-2021 and estimated to create US $13.80 billion opportunity in 2027 over 2021.

Prescription Drug

Prescription Drug segment was valued at US $12.47 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $24.07 billion by 2027. Prescription Drug segment represented US $2.23 billion opportunity over 2019-2021 and estimated to create US $9.36 billion opportunity in 2027 over 2021.